Pharmacokinetics of Colistin and Colistimethate Sodium After a Single 80-mg Intravenous Dose of CMS in Young Healthy Volunteers

被引:113
作者
Couet, W. [1 ,2 ,3 ]
Gregoire, N. [1 ,2 ]
Gobin, P. [1 ,3 ]
Saulnier, P. J. [4 ]
Frasca, D. [1 ,2 ,3 ]
Marchand, S. [1 ,2 ,3 ]
Mimoz, O. [1 ,2 ,4 ]
机构
[1] INSERM, ERI 23, Poitiers, France
[2] Univ Poitiers, Fac Med & Pharm, Poitiers, France
[3] CHU Poitiers, Poitiers, France
[4] INSERM, CIC 0802, Poitiers, France
关键词
PERFORMANCE LIQUID-CHROMATOGRAPHY; NEGATIVE BACTERIAL-INFECTIONS; CRITICALLY-ILL PATIENTS; MULTIDRUG-RESISTANT; METHANESULFONATE; RATS; PLASMA;
D O I
10.1038/clpt.2011.48
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Colistin pharmacokinetics (PK) was investigated in young healthy volunteers after a 1-h infusion of 80 mg (1 million international units (MIU)) of the prodrug colistin methanesulfonate (CMS). Concentration levels of CMS and colistin were determined in plasma and urine using a new chromatographic assay and analyzed simultaneously with a population approach after correcting the urine-related data for postexcretion hydrolysis of CMS into colistin. CMS and colistin have low volumes of distribution (14.0 and 12.4 liters, respectively), consistent with distribution being restricted to extracellular fluid. CMS is mainly excreted unchanged in urine (70% on average), with a typical renal clearance estimated at 103 ml/min-close to the glomerular filtration rate. Colistin elimination is essentially extrarenal, given that its renal clearance is 1.9 ml/min, consistent with extensive reabsorption. Colistin elimination is not limited by the formation rate because its half-life (3 h) is longer than that of CMS. The values of these pharmacokinetic parameters will serve as reference points for future comparisons with patients' data.
引用
收藏
页码:875 / 879
页数:5
相关论文
共 16 条
  • [1] ACUTE RENAL FAILURE DUE TO OVERDOSAGE OF COLISTIN
    BROWN, JM
    DORMAN, DC
    ROY, LP
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1970, 2 (20) : 923 - &
  • [2] Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections
    Falagas, ME
    Kasiakou, SK
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) : 1333 - 1341
  • [3] GARONZIK SM, 2010, 50 ANN INT C ANT AG
  • [4] Assay of Colistin and Colistin Methanesulfonate in Plasma and Urine by Liquid Chromatography-Tandem Mass Spectrometry
    Gobin, Patrice
    Lemaitre, Florian
    Marchand, Sandrine
    Couet, William
    Olivier, Jean-Christophe
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) : 1941 - 1948
  • [5] KOCH-WESER J, 1970, Annals of Internal Medicine, V72, P857
  • [6] Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate
    Li, J
    Milne, RW
    Nation, RL
    Turnidge, JD
    Smeaton, TC
    Coulthard, K
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (05) : 837 - 840
  • [7] Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration
    Li, J
    Milne, RW
    Nation, RL
    Turnidge, JD
    Smeaton, TC
    Coulthard, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) : 1766 - 1770
  • [8] Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography
    Li, J
    Milne, RW
    Nation, RL
    Turnidge, JD
    Coulthard, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) : 1364 - 1370
  • [9] Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
    Li, Jian
    Nation, Roger L.
    Turnidge, John D.
    Milne, Robert W.
    Coulthard, Kingsley
    Rayner, Craig R.
    Paterson, David L.
    [J]. LANCET INFECTIOUS DISEASES, 2006, 6 (09) : 589 - 601
  • [10] Renal Disposition of Colistin in the Isolated Perfused Rat Kidney
    Ma, Zheng
    Wang, Jiping
    Nation, Roger L.
    Li, Jian
    Turnidge, John D.
    Coulthard, Kingsley
    Milne, Robert W.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (07) : 2857 - 2864